Citrine Global Corp. (CTGL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Citrine Global Corp. (CTGL) trades at $0.01. Citrine Global Corp. specializes in plant-derived wellness and pharmaceutical solutions, developing botanical products and complementary remedies. The company, formerly TechCare Corp. Market cap: $9.02M, Sector: Industrials.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CTGL: CTGL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CTGL against Industrials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CTGL: 1/1 perspectives are bearish.
How is this calculated? →Citrine Global Corp. (CTGL) Industrial Operations Profile
Citrine Global Corp. (CTGL) is an Israel-based enterprise operating in the Specialty Business Services industry, focusing on plant-derived wellness and pharmaceutical solutions. The company develops botanical products and complementary remedies, aiming to enhance quality of life and alleviate side effects from various treatments, positioning itself in the growing health and wellness market.
What Is the Investment Thesis for CTGL?
Citrine Global Corp. (CTGL) presents an investment profile centered on its specialization in plant-derived wellness and pharmaceutical solutions, a segment benefiting from increasing consumer demand for natural health alternatives. The company's core value proposition lies in its mission to develop botanical products that enhance quality of life and offer complementary remedies to alleviate side effects from pharmaceuticals, cannabis use, medical treatments, and imbalanced lifestyles. This niche focus positions CTGL within a growing market for health and wellness products, as indicated by broader industry trends. Key considerations for investors include the company's current market capitalization of $9.02M, reflecting its micro-cap status, and a Beta of 2.78, suggesting significantly higher volatility compared to the broader market. Potential growth catalysts include the expansion of its product lines to address a wider array of side effects, strategic partnerships to enhance distribution, and increased market penetration in the burgeoning wellness sector. However, significant risk factors include its listing on the OTC Other tier, which typically entails lower liquidity and higher trading volatility. The company's ability to secure consistent funding and effectively expand its market reach will be critical determinants of its future trajectory, requiring close monitoring of operational execution and financial performance.
Based on FMP financials and quantitative analysis
CTGL Key Highlights
- Market Capitalization: $0.01 billion, indicating a micro-cap company status.
- Beta: 2.78, suggesting significantly higher volatility compared to the overall market.
- Employee Count: 18 employees, reflecting a relatively small operational scale.
- Dividend Policy: No dividend distribution, indicating a focus on reinvestment or early-stage development.
- Headquarters: Located in Herzliya, Israel, positioning it within an international innovation hub for health tech.
Who Are CTGL's Competitors?
CTGL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FTBGF Bidstack Group Plc | $0.03 | +20.00% | $29.04M | 63 |
| BUUU BUUU Group Limited provides meeting, incentive, conference, and exhibition solutions, including event management and stage production services. The company | $21.35 | -2.06% | $249.69M | 63 |
| ZGM Zenta Group Company Limited | $1.99 | +11.80% | $23.50M | 60 |
| INPOF InPost S.A. | $17.47 | +0.00% | $8.73B | 60 |
| GPN Global Payments Inc. | $77.83 | -1.01% | $18.42B | 50 |
| GLCDF GL Events S.A. | $18.40 | +0.00% | $540.18M | 51 |
| RELOF Relo Group, Inc. | $10.95 | -7.52% | $1.66B | 51 |
| IPHLF IPH Limited | $2.68 | +21.27% | $686.87M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CTGL's Key Strengths?
- Specialization in plant-derived wellness and pharmaceutical solutions, addressing a growing market segment.
- Focused mission on alleviating specific side effects from various treatments and lifestyle imbalances.
- Positioned within the expanding global beauty and wellness market, indicating potential demand.
- Established in 2010, providing a foundation of operational experience in the sector.
What Are CTGL's Weaknesses?
- Small scale of operations with 18 employees, potentially limiting capacity and reach.
- Market position not clearly defined, which may hinder competitive differentiation and investor clarity.
- Listing on the OTC Other tier, implying higher volatility and lower liquidity.
- Micro-cap market capitalization of $9.02M, often associated with higher investment risk.
What Could Drive CTGL Stock Higher?
- Growing global demand for beauty and wellness products, potentially increasing market opportunities for CTGL's plant-derived solutions.
- Potential securing of additional funding, which could enable expansion of market reach and product development efforts.
- Introduction of new plant-derived wellness or pharmaceutical solutions, expanding the company's product portfolio and revenue streams.
- Formation of strategic partnerships for distribution or product co-development, enhancing market penetration and operational capabilities.
What Are the Key Risks for CTGL?
- Financial-distress signal — its Altman Z-Score of -47.75 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Listing on the OTC Other tier, which typically indicates higher volatility and lower liquidity compared to major exchanges.
- The company's market position is not clearly defined, potentially hindering investor confidence and market penetration.
- Challenges in securing adequate funding to support product development, marketing, and market expansion initiatives.
- Intense competition within the plant-derived wellness and pharmaceutical solutions market from more established players.
- Regulatory hurdles and compliance costs associated with developing and marketing botanical and pharmaceutical-adjacent products.
What Are the Growth Opportunities for CTGL?
- Expansion into new botanical product lines: Leveraging its expertise in plant-derived solutions, CTGL could develop and introduce a wider range of wellness products. This opportunity is driven by the increasing consumer demand for natural health alternatives, a trend highlighted by the AI insight regarding the growing beauty and wellness market. By diversifying its product portfolio, the company could capture a larger share of this expanding market, potentially attracting new customer segments seeking specialized botanical remedies and enhancing its revenue streams over the medium term.
- Strategic partnerships for market reach: Collaborating with established pharmaceutical distributors, wellness retailers, or e-commerce platforms could significantly expand CTGL's market penetration beyond its current operational scope. Such partnerships would allow the company to leverage existing distribution networks and brand recognition, accelerating product adoption. This approach is crucial for an emerging player, as noted in the AI insight, to overcome challenges in securing funding and expanding market reach, potentially leading to increased sales volumes within the next 2-3 years.
- Research and development in specific therapeutic areas: Focusing R&D efforts on plant-derived solutions for particular medical conditions or side effects, such as those from specific pharmaceutical treatments or chronic conditions, could create highly specialized and high-value products. This aligns with CTGL's mission to alleviate side effects and enhance quality of life. Developing proprietary formulations could establish a strong competitive advantage and intellectual property, differentiating its offerings in a crowded wellness market and securing long-term revenue potential.
- Geographic expansion, particularly within wellness-conscious European and North American markets: While headquartered in Israel, CTGL has the opportunity to target international markets with strong demand for plant-derived wellness products. Expanding into regions with high disposable income and a cultural inclination towards natural health could significantly increase its customer base and revenue streams. This expansion would require careful market entry strategies, potentially through local partnerships or direct-to-consumer models, and could unfold over a 3-5 year timeline, significantly broadening its addressable market.
- Digital marketing and direct-to-consumer sales channels: Investing in robust digital marketing strategies and establishing strong direct-to-consumer (DTC) e-commerce platforms could enhance brand visibility and sales efficiency. This approach allows CTGL to directly engage with consumers, gather feedback, and build brand loyalty without relying solely on traditional retail channels. Given the global demand for beauty and wellness products, a strong online presence is critical for reaching a broad audience and managing customer relationships effectively, offering a scalable growth path over the next 1-2 years.
What Opportunities Does CTGL Have?
- Growing global demand for natural and plant-derived health products and complementary medicines.
- Potential to expand product lines and market reach by leveraging its specialized botanical expertise.
- Formation of strategic partnerships to enhance distribution networks and secure additional funding.
- Leveraging its unique focus on alleviating specific side effects to capture underserved market segments.
What Threats Does CTGL Face?
- Intense competition from established pharmaceutical companies and numerous wellness brands.
- Potential regulatory challenges and compliance costs in the plant-derived and pharmaceutical solutions space.
- Difficulty in securing adequate funding and expanding market reach, as noted in AI insights.
- High market volatility and low liquidity inherent with trading on the OTC Other tier.
What Are CTGL's Competitive Advantages?
- Specialized focus on plant-derived wellness and pharmaceutical solutions, creating a distinct niche.
- Expertise in developing botanical products and complementary remedies for specific ailments.
- Potential for proprietary formulations and intellectual property in plant-based health solutions.
- Mission-driven approach to enhance quality of life and alleviate specific side effects, fostering brand loyalty.
What Does CTGL Do?
Citrine Global Corp., headquartered in Herzliya, Israel, operates as an enterprise specializing in plant-derived wellness and pharmaceutical solutions. Established in 2010, the company initially operated under the name TechCare Corp. before undergoing a strategic rebranding to Citrine Global Corp. in August 2020. This evolution reflects a refined focus on its core mission: to develop botanical products specifically designed to enhance the quality of life for consumers. With a team of 18 employees, Citrine Global is dedicated to innovation within the health and wellness sector, leveraging its expertise in botanical science. The company's product development extends beyond general wellness, encompassing a crucial area of complementary remedies. These solutions are meticulously designed to alleviate a range of side effects that can stem from various sources. This includes adverse reactions associated with conventional pharmaceuticals, discomfort or issues arising from cannabis use, and undesirable effects from other medical treatments. Furthermore, Citrine Global addresses side effects linked to an imbalanced lifestyle, offering natural alternatives to support overall well-being. By targeting these specific needs, the company positions itself as a provider of specialized botanical interventions, aiming to fill gaps in the market where traditional treatments may fall short or cause secondary issues. While operating in the Industrials sector, its product focus aligns with the broader consumer demand for beauty and wellness products, indicating its potential as an emerging player in a globally expanding market. The company's strategic location in Israel, a hub for biotech and health innovation, may also provide access to a rich ecosystem of research and development resources.
What Products and Services Does CTGL Offer?
- Develops plant-derived wellness solutions.
- Creates botanical products to enhance quality of life.
- Offers complementary remedies.
- Aims to alleviate side effects from pharmaceuticals.
- Addresses side effects from cannabis use.
- Provides solutions for side effects from various medical treatments.
- Develops remedies for side effects stemming from an imbalanced lifestyle.
- Operates in the Specialty Business Services industry.
How Does CTGL Make Money?
- Research, develop, and market plant-derived wellness products.
- Generate revenue through sales of botanical solutions and complementary remedies.
- Focus on niche markets addressing specific side effects and quality of life improvements.
- Potentially engage in direct-to-consumer sales or wholesale distribution channels.
What Industry Does CTGL Operate In?
Citrine Global Corp. operates within the Specialty Business Services industry, with a distinct product focus on plant-derived wellness and pharmaceutical solutions. This segment is experiencing tailwinds from a global shift towards natural health remedies and complementary medicine, driven by increasing consumer health consciousness and a desire for holistic well-being. The broader beauty and wellness market, as highlighted by AI insights, is undergoing significant growth, creating a fertile ground for companies like CTGL. As an emerging player, Citrine Global aims to carve out a specific niche by addressing the side effects of conventional treatments and imbalanced lifestyles. Its positioning requires navigating a competitive landscape populated by both established pharmaceutical giants and a multitude of smaller, specialized wellness brands, necessitating clear differentiation and effective market penetration strategies.
Who Are CTGL's Key Customers?
- Individuals seeking natural wellness solutions.
- Consumers looking for remedies to alleviate side effects from medical treatments.
- People experiencing discomfort from cannabis use.
- Individuals aiming to improve quality of life through botanical products.
- Health-conscious consumers interested in plant-derived solutions.
Net buyingInsider Activity
The most recent 12 insider filings for Citrine Global Corp. break down as 4 sales and 8 purchases. On net that is roughly 520.2M shares acquired (about $18K) — insiders putting money in tends to read as conviction.
F-Score 1/9Financial Health
Citrine Global Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -47.75 places it in the distress zone, a signal of elevated financial risk.
ROE 47%Key Financial Metrics
Return on equity for Citrine Global Corp. stands at 47.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -6.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -16.1%, the inverse of the P/E and a quick read on earnings relative to price.
Citrine Global Corp. (CTGL) Valuation Context
Valued at $9.02M, CTGL is classified as a micro-cap stock.
Company Profile
Citrine Global Corp. operates in the Specialty Business Services industry within the Industrials sector. It is headquartered in Herzliya, IL. The company is led by CEO Ora Elharar Soffer. CTGL has traded publicly since 2012.
CTGL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Citrine's recent insider buying signals strong confidence from within, suggesting leadership believes the company is undervalued.
- The community's positive sentiment towards CTGL's strategic partnerships indicates growing trust in their expansion plans.
- Market perception of CTGL as an emerging player in sustainable solutions is attracting environmentally conscious investors.
- Bullish community members highlight CTGL's innovative approach to global trade, anticipating significant market disruption.
Bear Case
- Recent bearish community chatter suggests concerns about CTGL's ability to scale operations effectively.
- Market perception of increased competition in the global trade sector is creating headwinds for CTGL's growth narrative.
- Some community members express skepticism regarding the long-term viability of CTGL's business model in fluctuating economic conditions.
- Insider activity, while showing buys, also includes some sales, potentially indicating mixed sentiments within the company leadership.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CTGL Latest News
No recent news available for CTGL.
CTGL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CTGL.
Price Targets
Wall Street price target analysis for CTGL.
CTGL MoonshotScore
What does this score mean?
The MoonshotScore rates CTGL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Specialty Business ServicesLeadership: Ora Elharar Soffer
CEO
Unknown
Track Record: Unknown
CTGL OTC Market Information
The OTC Other tier, where Citrine Global Corp. (CTGL) trades, represents the lowest and most speculative tier of the over-the-counter market. Unlike major exchanges such as the NYSE or NASDAQ, which have stringent listing requirements regarding financial health, corporate governance, and minimum share prices, the OTC Other tier has minimal to no such requirements. This tier is typically home to companies that are either very early-stage, distressed, or have limited public information, making them inherently riskier. It signifies a lack of comprehensive financial disclosure and regulatory oversight compared to higher OTC tiers or national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Higher price volatility due to low trading volume and limited liquidity.
- Lack of comprehensive financial disclosure, making fundamental analysis challenging.
- Increased susceptibility to pump-and-dump schemes and market manipulation.
- Difficulty in raising capital due to the speculative nature of the tier.
- Limited analyst coverage and institutional investor interest.
- Verify the company's current financial statements and reports, if any are available.
- Research the management team's background and track record beyond what's publicly disclosed.
- Assess the viability and market demand for their specific plant-derived products.
- Investigate any recent news, press releases, or regulatory filings for operational updates.
- Understand the competitive landscape and CTGL's specific market niche.
- Evaluate the company's capital structure and potential need for future funding.
- Examine the trading volume and bid-ask spread to gauge liquidity.
- Clear and consistent business description with a defined product focus.
- Headquarters in Herzliya, Israel, suggesting a physical operational base.
- Stated mission to develop botanical products and complementary remedies.
- Rebranding from TechCare Corp. to Citrine Global Corp. in 2020, indicating strategic evolution.
- Identified CEO, Ora Elharar Soffer, managing the company's 18 employees.
CTGL Industrials Stock FAQ
What does Citrine Global Corp. do?
Citrine Global Corp. (CTGL) is an enterprise based in Herzliya, Israel, specializing in the development and marketing of plant-derived wellness and pharmaceutical solutions. The company's core business involves creating botanical products aimed at enhancing overall quality of life. Additionally, CTGL focuses on developing complementary remedies specifically designed to alleviate side effects. These side effects can stem from various sources, including conventional pharmaceuticals, cannabis use, diverse medical treatments, or an imbalanced lifestyle. Established in 2010 as TechCare Corp. before rebranding in 2020, CTGL operates in the Specialty Business Services industry, positioning itself as a provider of natural, targeted health solutions.
What are the key financial metrics investors watch for CTGL?
For Citrine Global Corp., investors typically monitor several key financial metrics given its operational stage and market listing. The company's market capitalization of $9.02M indicates it is a micro-cap entity, often associated with higher risk and growth potential. Its Beta of 2.78 suggests significant price volatility relative to the broader market, which is a critical factor for risk assessment. As a company that does not pay dividends, investors would focus on growth metrics, such as revenue expansion from new product introductions or market penetration. Additionally, due to its OTC Other listing, investors would closely scrutinize any available financial disclosures for cash flow, profitability, and funding activities, as these are crucial for its operational sustainability and expansion.
What are the main risks for CTGL, especially as an OTC-listed company?
Citrine Global Corp. faces several significant risks, particularly due to its listing on the OTC Other tier. This tier is characterized by higher volatility and lower liquidity compared to major exchanges, making it challenging for investors to trade shares efficiently and potentially leading to substantial price swings. Furthermore, the company's market position is not clearly defined, which can create uncertainty regarding its competitive advantage and long-term growth trajectory. A critical ongoing risk is the potential difficulty in securing sufficient funding to support its research, development, and market expansion efforts. The specialized nature of plant-derived wellness and pharmaceutical solutions also exposes CTGL to intense competition from both established pharmaceutical firms and numerous emerging wellness brands, alongside potential regulatory hurdles in product development and marketing.
What are the key factors to evaluate for CTGL?
Evaluate CTGL on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does CTGL data refresh on this page?
CTGL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CTGL's recent stock price performance?
Citrine Global Corp. (CTGL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in plant-derived wellness and pharmaceutical solutions, addressing a growing market segment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CTGL overvalued or undervalued right now?
Valuing Citrine Global Corp. (CTGL) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CTGL?
Before investing in Citrine Global Corp. (CTGL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data provided.
- No specific details on CEO's background or track record available.
- No FMP PEER TICKERS provided for competitor analysis.
- Market size and timeline data for growth opportunities are inferred from general market trends mentioned in AI insight, not explicit company data.